{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Solid+Tumors&page=13",
    "query": {
      "condition": "Locally Advanced Solid Tumors",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 449,
    "total_pages": 45,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Solid+Tumors&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Solid+Tumors&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:49:09.209Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03744468",
      "title": "Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in",
        "HNSCC for Phase 2 Dose Expansion",
        "NSCLC for Phase 2 Dose Expansion"
      ],
      "interventions": [
        {
          "name": "Surzebiclimab",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Alcestobart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2018-11-13",
      "completion_date": "2025-02-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 11,
      "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03744468"
    },
    {
      "nct_id": "NCT05646797",
      "title": "A Study of ASP2074 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP2074",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2023-02-28",
      "completion_date": "2024-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 8,
      "location_summary": "Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05646797"
    },
    {
      "nct_id": "NCT04383210",
      "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Pancreatic Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Kidney Cancer",
        "Colorectal Cancer",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Gallbladder Cancer",
        "Bile Duct Cancer",
        "Esophageal Cancer",
        "Uterine Cancer",
        "Cholangiocarcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Seribantumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevation Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-09-29",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383210"
    },
    {
      "nct_id": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Resectable Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "INBRX-106 - Hexavalent OX40 agonist antibody",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 200 mg",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-5",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-6",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed 500 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin 75mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel 100mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (1000 mg/m2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2019-12-10",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 39,
      "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 32 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04198766"
    },
    {
      "nct_id": "NCT04606446",
      "title": "Study of PF-07248144 in Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic ER+ HER2- Breast Cancer",
        "Locally Advanced or Metastatic Castration-resistant Prostate Cancer",
        "Locally Advanced or Metastatic Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07248144",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060",
          "type": "DRUG"
        },
        {
          "name": "PF-07850327, ARV-471, vepdegestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2020-11-16",
      "completion_date": "2029-08-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 22,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04606446"
    },
    {
      "nct_id": "NCT05722288",
      "title": "Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Localized Prostate Carcinoma",
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Rectal Carcinoma",
        "Malignant Solid Neoplasm",
        "Recurrent Prostate Carcinoma",
        "Stage I Prostate Cancer AJCC v8",
        "Stage IB Cervical Cancer FIGO 2018",
        "Stage IB2 Cervical Cancer FIGO 2018",
        "Stage II Prostate Cancer AJCC v8",
        "Stage II Rectal Cancer AJCC v8",
        "Stage IIA Cervical Cancer FIGO 2018",
        "Stage IIB Cervical Cancer FIGO 2018",
        "Stage III Prostate Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8",
        "Stage IIIA Cervical Cancer FIGO 2018",
        "Stage IIIB Cervical Cancer FIGO 2018",
        "Stage IIIC Cervical Cancer FIGO 2018",
        "Stage IVA Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Short-Term Fasting",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2023-03-23",
      "completion_date": "2027-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05722288"
    },
    {
      "nct_id": "NCT04294576",
      "title": "Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BJ-001",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BJ Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2019-12-04",
      "completion_date": "2024-10-22",
      "has_results": false,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294576"
    },
    {
      "nct_id": "NCT05970497",
      "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Melanoma Stage III",
        "Melanoma Stage IV",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "KB707",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Opdualag",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA ®( Pembrolizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-10-31",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05970497"
    },
    {
      "nct_id": "NCT03950297",
      "title": "Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "609A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-05-01",
      "completion_date": "2022-05-24",
      "has_results": false,
      "last_update_posted_date": "2020-04-03",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03950297"
    },
    {
      "nct_id": "NCT04887831",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Myelosuppression Adult",
        "Chemotherapy-induced Neutropenia",
        "Metastatic Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2021-06-04",
      "completion_date": "2024-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-11-18T23:49:09.209Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887831"
    }
  ]
}